Texas lawmakers vote to override governor’s vaccine order

Share this article:
Texas lawmakers voted to approve a bill blocking Republican Gov. Rick Perry’s order requiring sixth grade girls to be vaccinated against human papillomavirus (HPV). Last week, the Texas House voted 119-21 to approve a bill to keep the HPV vaccine off the required list of shots for school attendance. The measure still needs final approval from the state House and the Senate. It is possible that Perry could veto the legislation; however, the bill does have enough backing, with 119 votes, to override such a veto. In February, Perry signed an order making Texas the first state to require schoolgirls be vaccinated against HPV, the virus that causes cervical cancer. The action came on the heels of intense lobbying efforts in Texas by Merck, the maker of Gardasil, which is currently the only approved vaccine available to protect girls and women against strains of HPV responsible for most cases of cervical cancer. GlaxoSmithKline is also working on a developmental HPV vaccine, known as Cervarix. The company plans to file for FDA approval of Cervarix in April. In late February, Merck said it would stop lobbying states to pass laws requiring that preteen girls be vaccinated against cervical cancer, following a growing backlash among parents, healthcare providers and consumer groups. Meanwhile, New Mexico Gov. Bill Richardson, a Democrat, will sign legislation approved by the state House on Sunday requiring vaccinations against HPV for sixth grade girls. The legislation is set to take effect June 15. Virginia lawmakers have passed a similar law, which Democratic Gov. Timothy Kaine has said he would sign. In Massachusetts, Democratic Gov. Deval Patrick’s budget proposal calls for providing the vaccine free to all girls ages 9 through 18 who want it.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...